Clostridium difficile infection: new developments in epidemiology and pathogenesis

By M. Rupnik, M. Wilcox, D. Gerding. Nature Reviews Microbiology, 2009

1,433 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/b5b10a93cbc209adc5b842e32881ba9cbef847d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Khoruts
2. P. Mullany

In Infectious Diseases

1. A. Khoruts
2. T. Borody

Citations in the corpus

• Consequences of bile salt biotransformations by intestinal bacteria (2016, background): “difficile, the cause of antibiotic-associated diarrhea and colitis, is a growing health threat for patients taking broad spectrum antibiotics.(115) It has been estimated that C.”
• Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling (2014, background): “Clinical isolates of C. difficile were obtained from M. Wilcox (United Kingdom), M. Miller (Canada), D. Gerding (United States), H. Kato (Japan), or tgcBIOMICS (western Europe) (for a complete list, see Table S1 in the supplemental material).”
• Fecal microbiota transplantation and emerging applications (2012, background): “difficile strains with increased virulence, such as PCR ribotype 027/North American Pulsed-field type 1 (NAP1), which is characterized by resistance to fluoroquinolones and increased toxin production attributable to a mutation in tcdC , as well as binary toxin production”
• Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. (2014, neutral): “3) [11-89] 3 (3-5) [2-6] 10 (8-15) [6-30] 5 (5-7) [2-9] 4.”
• Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances (2016, background): “…aureus and, of most concern, Clostridium difficile, which can cause intractable, long-term recurrent infections and even a potentially lethal pseudomembranous colitis (Wilcox, 2003; Young and Schmidt, 2004; Song et al., 2008; Rupnik et al., 2009; Sekirov et al., 2010; Chen et al., 2013).”
• Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography (2014, methodology): “Furthermore, the residues of TcdB defined herein as being involved in carbohydrate binding are based on the structure of TcdA bound to -Gal-(1,3)- -Gal-(1,4)- GlcNAcO(CH2)8CO2CH3, and it is possible that the TcdB ligand interacts with different residues (encompassing a smaller or larger surface area”